Skip to main content

Hematopathology Eligible or CAR-t Cell Treatment

0
Pipeline Programs
4
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
5100%

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)N/ACell Therapy
French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)N/ACell Therapy
Bristol Myers Squibb
1 program
French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)N/ACell Therapy
Kite Pharma
Kite PharmaCA - El Segundo
1 program
French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)N/ACell Therapy
Sandoz
SandozAustria - Kundl
1 program
French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)N/ACell Therapy1 trial
Active Trials
NCT04328298Recruiting5,000Est. Dec 2038

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
SandozFrench Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Clinical Trials (1)

Total enrollment: 5,000 patients across 1 trials

NCT04328298SandozFrench Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Start: Dec 2019Est. completion: Dec 20385,000 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 5,000 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.